- Endonovo Therapeutics is developing a bioceutical device that provides an alternative to the prescription pain pills blamed for hundreds of thousands of deaths in recent years as part of a multinational opioid crisis
- Endonovo’s proprietary SofPulse® flagship device provides an electrical micro-current to the afflicted part of the body, particularly post-surgery, to minimize a patient’s need for pain relief medication
- A foot and ankle specialist in Ohio recently used the device following her own tendon surgery and provided a personal testimonial with a professional perspective of the device’s effectiveness in minimizing her pain
- The SofPulse® device is being evaluated professionally under a plan to be in up to 600 U.S. hospitals by the end of next year
When a foot and ankle medical specialist underwent surgery recently for her own tendon reconstruction need, she presented bioelectronic device maker Endonovo Therapeutics Inc. (OTCQB: ENDV) with a first-person professional perspective of Endonovo’s non-opioid pain relief solution that showcases Endonovo’s revolutionary potential for alleviating an international drug-dependency crisis.
In a home-made video, Dr. Jane Graenber, DPM, of the Foot and Ankle Wellness Center in Delaware, Ohio, attests that Endonovo’s SofPulse® electroceutical device has helped her to remain generally pain-free a day after the tendon surgery, such that she says she has only used three doses of Tylenol for relief (no prescription pain pills) during the interim since her procedure (http://ibn.fm/H2n5X).
“This device is putting out a micro-current to my surgical area every two hours… And it’s taken care of the pain, and I’m sitting here very comfortably,” Graenber states in the video. “At our practice we may be starting to include this post-operatively as an option to reduce pain. This was a pretty big surgery and I’m really very comfortable. So I’m giving credit to a good surgeon but also a new device that may revolutionize pain (treatment) after surgery.”
Endonovo announced its initial strategy to begin a national rollout of the SofPulse® on June 13 with plans to be in the evaluation stage at 600 U.S. hospitals through the end of next year (http://ibn.fm/P0w4a). Graenber identifies the video’s date as August 3, countering a time stamp at the bottom of the video that says it was recorded in January 2015.
The proliferation of opioids for pain relief following medical procedures during the past two decades has generated worldwide concerns about the prescription pills’ apparent role in creating patients’ ensuing drug addictions – addictions that have been cited in the deaths of hundreds of thousands of people. The Centers for Disease Control and Prevention states that as of 2017, its statistics showed an average of 130 Americans were dying every day from an opioid overdose (http://ibn.fm/4e49T).
The concerns about opioid abuse have sparked a multi-national sea change in attitudes regarding marijuana use as a medical therapy, although the cannabis plant’s products remain controversial with many governmental regulators. Endonovo’s SofPulse® provides a non-drug alternative to treating pain relief, entirely bypassing concerns about potential substance abuse and harmful side effects.
Furthermore, a recent scientific study of patient outcomes is countering the popularly held idea that marijuana reform is reducing the number of opioid-related deaths. The study published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) in June found that states where cannabis legislation has eased access to medical marijuana as an alternative to opioids have actually seen an increase in opioid-related deaths in recent years, rather than a decrease (http://ibn.fm/0BsyR).
“Cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,” the study states.
Endonovo’s therapy platform has received clearance for the palliative treatment of post-operative pain and swelling from the U.S. Federal Drug Administration, insurance coverage for chronic wound treatment from the national Centers for Medicare and Medicaid Services, and a CE-mark certification that denotes conformity with European Economic Area health and environmental standards related to wound, pain and edema treatment.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV